What is retatrutide and how does it work?
Retatrutide is Eli Lilly’s investigational triple-hormone receptor agonist targeting the GLP-1, GIP, and glucagon receptors. It enhances insulin secretion, suppresses appetite, and elevates energy expenditure, producing up to 30.3% average weight reduction in clinical trials. Unlike single-pathway GLP-1 drugs such as semaglutide, retatrutide acts on three metabolic pathways at once. That triple mechanism is why it is being studied as a potential step-change in obesity treatment.
Mechanism summary
Retatrutide simultaneously activates receptors for three gut hormones:
- GLP-1 receptor — appetite suppression and blood-sugar control.
- GIP receptor — potentiates the incretin effect and insulin sensitivity.
- Glucagon receptor — raises energy expenditure.
This combination is designed to produce greater weight loss than GLP-1-only or GLP-1+GIP therapies while remaining a single weekly injection.
How much weight loss does retatrutide cause in clinical trials?
In the Phase 3 TRIUMPH-1 trial, adults without diabetes on the 12 mg dose achieved a mean weight loss of 28.3% at 80 weeks and 30.3% (85.0 lb) at 104 weeks in extended dosing. Lower doses delivered 19.0% (4 mg) and 25.9% (9 mg) average reductions, and up to 45.3% of 12 mg participants lost 30% or more of their total body weight.
TRIUMPH trial results by cohort
| Trial | Cohort | 12 mg mean weight loss | Duration |
|---|---|---|---|
| TRIUMPH-1 | Adults without diabetes | 28.3% (70.3 lb) | 80 weeks |
| TRIUMPH-1 extended | Adults without diabetes | 30.3% (85.0 lb) | 104 weeks |
| TRIUMPH-2 | Type 2 diabetes | ~21% | 80 weeks |
| TRIUMPH-3 | Established cardiovascular disease | ~23% | 80 weeks |
A threshold of 30% or more total body weight loss has historically been seen almost exclusively with bariatric surgery, which is why retatrutide’s 45.3% achievement rate at that level drew attention.
How does retatrutide compare to Mounjaro and Ozempic?
Compared with the approved GLP-1 class, retatrutide shows stronger headline efficacy because it adds the glucagon-receptor pathway. Semaglutide and tirzepatide remain the current reference standards, but neither appears to reach the 30% mean weight-loss range seen with retatrutide at 12 mg.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Retatrutide (Triple-G) |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist | Triple GLP-1 + GIP + glucagon agonist |
| Peak weight loss | ~15% body weight | ~20-22% body weight | Up to 30.3% body weight |
| A1C impact | -1.5% to -1.8% | -2.0% to -2.3% | Up to -2.0% (TRANSCEND-T2D-1) |
| FDA status | FDA approved | FDA approved | FDA filing expected early 2027 |
Comorbidity and secondary endpoints
Beyond weight, Phase 3 data showed meaningful effects on weight-related conditions:
- Type 2 diabetes: the 40-week TRANSCEND-T2D-1 study measured A1C reductions up to 2.0 percentage points from a 7.9% baseline.
- Knee osteoarthritis: pain subscale scores dropped up to 4.3 points (73.1% reduction).
- Obstructive sleep apnea: apnea-hypopnea index fell up to 36.1 events/hour (60.6% reduction).
- Cardiometabolic markers: improvements in systolic blood pressure, waist circumference (up to 24.1 cm), triglycerides (down 37%), and non-HDL cholesterol.
What are the most common side effects of retatrutide?
The most frequent adverse events are gastrointestinal, consistent with the GLP-1/GIP/glucagon class. At the 12 mg dose, nausea occurred in up to 42.4%, diarrhea in up to 34.1%, constipation in up to 26.1%, and vomiting in up to 25.3%. Discontinuation due to side effects rose with dose at 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg), versus 4.9% on placebo.
When will retatrutide be FDA approved and available?
Eli Lilly plans to file for FDA approval in early 2027 following completion of safety and durability extensions. Market availability is projected for late 2027 or early 2028 depending on regulatory review timelines. Retatrutide currently has no brand name and remains an investigational compound.
Key takeaways
- Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon) in Phase 3, not yet approved.
- Top dose shows up to 30.3% mean weight loss; 45.3% of participants lost 30%+.
- FDA filing planned for early 2027; availability likely late 2027-2028.
- Side-effect profile is gastrointestinal, similar to the rest of the class.